Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Andrea Borghese Apolo, Karla V. Ballman, Guru Sonpavde et al. · New England Journal of Medicine · 2024
BACKGROUND: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. METHODS: In this phase 3 trial, we randomly assigned patients, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks for 1 year or to undergo observation. Randomization was stratified according to pathological stage, centrally tested programmed death ligand 1 (PD-L1) status, and previous neoadjuvant chemotherapy. The coprimary end points were disease-free survival and overall survival in the intention-to-treat population. We considered the trial to be successful if either disease-free survival or overall survival was significantly longer with pembrolizumab than with observation. RESULTS: A total of 702 patients underwent randomization; 354 were assigned to receive pembrolizumab, and 348 were assigned to observation. As of July 5, 2024, the median duration of follow-up for disease-free survival was 44.8 months. The median disease-free survival was 29.6 months (95% confidence interval [CI], 20.0 to 40.7) with pembrolizumab and 14.2 months (95% CI, 11.0 to 20.2) with observation (hazard ratio for disease progression or death, 0.73; 95% CI, 0.59 to 0.90; two-sided P = 0.003). Grade 3 or higher adverse events (regardless of attribution) occurred in 50.6% of the patients in the pembrolizumab group and in 31.6% of the patients in the observation group. CONCLUSIONS: Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation. (Funded by the National Cancer Institute of the National Institutes of Health and others; Alliance A031501 AMBASSADOR ClinicalTrials.gov number, NCT03244384.).
Cited by 168 works. doi:10.1056/nejmoa2401726 Open-access PDF
Authors
- Andrea Borghese Apolo
- Karla V. Ballman
- Guru Sonpavde
- Stephanie A Berg
- William Y. Kim
- Rahul Atul Parikh
- Min Yuen Teo
- Randy F. Sweis
- Daniel M. Geynisman
- Petros D. Grivas
- Gurkamal S. Chatta
- Zachery Roger Reichert
- Joseph W. Kim
- Mehmet Asım Bilen
- Bradley Alexander McGregor
- Parminder Pal Singh
- Abhishek Tripathi
- Suzanne Cole
- Nicholas I. Simon
- Scot Anthony Niglio
References
- Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
- Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
- Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
- Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience